证券代码： 603259 证券简称：药明康德 公告编号：临 2023-059 无锡药明康德新药开发股份有限公司 本次多肽生产车间产能扩建项目将大幅提升本公司的多肽生产产能以及 WuXi TIDES 平台能力，巩固和提升本公司在全球范围内的市场竞争力，支持本 公司长远发展，同时亦可更好地满足全球合作伙伴在多肽药物开发与生产方面 日益增长的需求，为广大患者带来更多创新疗法。 三、风险提示 本次多肽生产车间产能扩建项目完成后完全达产、释放产能尚需一定时间， 后续生产亦可能面临潜在风险，包括但不限于未来可能存在市场环境变化、行 1 业政策变化、竞争加剧、终端需求调整等风险。敬请广大投资者注意投资风险。 特此公告。 下属子公司合全药业多肽生产车间产能扩建项目的自愿性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 目前无锡药明康德新药开发股份有限公司（以下简称"本公司"）下属子公 司上海合全药业股份有限公司（以下简称"合全药业"）在常州和泰兴两个生产 基地进行多肽生产车间产能扩建项目（以下简称"本次多肽生产车间产能扩建 项目"）。本 ...

二、本次限制行权期为 2023 年 10 月 1 日至 2023 年 10 月 30 日（包含首尾 两日），在此期间全部激励对象将限制行权。 三、公司将按照有关规定及时办理限制行权相关事宜。 特此公告。 证券代码：603259 证券简称：药明康德 公告编号：临 2023-058 无锡药明康德新药开发股份有限公司 关于 2019 年限制性股票与股票期权激励计划首次授予股票期权 第三个行权期限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》、上海证券交易所《上市公司自律监管 指南第八号——股权激励计划股票期权自主行权》《无锡药明康德新药开发股份 有限公司 2019 年限制性股票与股票期权激励计划（草案）》及中国证券登记结 算有限责任公司上海分公司（以下简称"中证登上海分公司"）关于股票期权自 主行权的相关规定，并结合无锡药明康德新药开发股份有限公司（以下简称"公 司"）2023 年第三季度报告披露计划，现对公司 2019 年限制性股票与股票期权 激励计划首次授予股票期权（以下 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 18,871.3 million, representing a 6.3% increase from RMB 17,756.3 million in the same period of 2022[8]. - Gross profit increased by 17.6% to RMB 7,555.7 million, with a gross margin of 40.0%, up from 36.2% in the previous year[8]. - Net profit attributable to shareholders rose by 14.6% to RMB 5,313.1 million, with a net profit margin of 28.2%, compared to 26.1% in 2022[8]. - Adjusted net profit attributable to shareholders was RMB 5,094.7 million, an 18.5% increase from RMB 4,300.7 million in the prior year[8]. - The company achieved revenue of RMB 18,871.3 million, a year-on-year increase of 6.3%, and net profit attributable to shareholders of RMB 5,313.1 million, up 14.6% year-on-year[9]. - The company reported a basic earnings per share of RMB 1.81, reflecting a 13.8% increase from RMB 1.59 in the same period last year[8]. - The adjusted basic earnings per share was RMB 1.73, an increase of 17.7% from RMB 1.47 in the previous year[8]. - Net profit for the period increased by 14.6% to RMB 5,356.9 million, with a net profit margin rising from 26.3% to 28.4%[24]. - The total comprehensive income for the period attributable to equity holders was RMB 4,806,967 thousand, an increase of 10.7% from RMB 4,342,460 thousand in the prior year[194]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 69,319.1 million, a 7.2% increase from RMB 64,690.3 million at the end of 2022[8]. - Total liabilities increased by 7.6% to RMB 19,120.4 million, compared to RMB 17,763.7 million in the previous year[8]. - Cash and cash equivalents rose by 20.1% to RMB 9,585.0 million, up from RMB 7,983.9 million at the end of 2022[8]. - The debt-to-asset ratio remained stable at 27.6%, slightly up from 27.5% at the end of 2022[8]. - As of June 30, 2023, total assets amounted to RMB 41,739,069 thousand, an increase from RMB 40,693,101 thousand as of December 31, 2022, representing a growth of approximately 2.57%[195]. - The company's net equity as of June 30, 2023, was RMB 50,198,782 thousand, compared to RMB 46,926,673 thousand at the end of 2022, marking an increase of around 4.83%[196]. - The total liabilities decreased from RMB 14,499,361 thousand to RMB 16,363,159 thousand, indicating a rise of approximately 12.87%[195]. Revenue Sources and Client Growth - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months, leading to a 25% year-on-year increase in orders excluding COVID-19 commercialization projects[9]. - Revenue from U.S. clients reached RMB 12.37 billion, a 42% year-on-year increase when excluding COVID-19 projects; revenue from European clients was RMB 2.22 billion, up 19%[9]. - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year, with a strong growth of 36.1% when excluding COVID-19 projects[10]. - The WuXi Testing segment reported revenue of RMB 3,091.0 million, an 18.7% year-on-year increase, with laboratory analysis and testing services contributing RMB 2,250 million, up 18.8%[12]. - The WuXi Biology segment achieved revenue of RMB 1,232.6 million, a 13.0% increase year-on-year, with new molecular-related revenue growing by 51%[13]. - The company’s D&M (Development and Manufacturing) revenue reached RMB 9.67 billion, a 2.1% increase year-on-year, with a strong growth of 54.5% when excluding COVID-19 projects[11]. - Approximately 99% of the company’s revenue came from existing clients, totaling RMB 18.65 billion, a 30% year-on-year increase when excluding COVID-19 projects[9]. Operational Efficiency and Cost Management - The net cash flow from operating activities for the six months ended June 30, 2023, was RMB 5,340.7 million, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022, driven by stable revenue collection and optimized working capital management[25]. - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,307.8 million, a decrease of 65.3% from RMB 3,770.1 million in the same period of 2022, primarily due to timing differences in project settlements leading to reduced capital expenditures[26]. - The net cash used in financing activities for the six months ended June 30, 2023, was RMB 2,612.8 million, an increase of 129.7% compared to RMB 1,137.6 million for the same period in 2022, mainly due to increased cash dividend payments during the reporting period[27]. - The company reported a decrease in cash outflow for the purchase of property, plant, and equipment to RMB 2,296,036 thousand in 2023 from RMB 4,359,857 thousand in 2022, indicating improved capital efficiency[199]. Research and Development - Research and development expenses for the period were RMB 667,045 thousand, slightly up from RMB 657,200 thousand in the previous year[193]. - The company is developing multiple potential FIC/BIC molecules for various cancers, with the first clinical trial application for the brain tumor probe BR-02 accepted by CDE and the BR-11 tumor treatment drug set to start IIT clinical trials in Q3 2023[41]. - The company is committed to leveraging cutting-edge technologies, such as medical big data and automated laboratories, to enhance operational efficiency and reduce drug development barriers[44]. Shareholder and Incentive Plans - The company has established a share incentive plan in place to motivate and retain employees[181]. - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares to shareholders listed on June 13, 2023[52]. - The board approved the 2023 H-share incentive trust plan on April 24, 2023, to enhance the company's compensation policy[164]. - The company aims to enhance its long-term incentive mechanism to attract and retain talent, ensuring sustainable development[116]. Market Outlook and Strategic Goals - The global pharmaceutical market is expected to continue growing due to economic development, population growth, aging, increased healthcare spending, and rising health awareness[60]. - The demand for pharmaceutical R&D services is anticipated to grow rapidly as large pharmaceutical companies increase outsourcing and small to medium-sized companies seek integrated R&D services[60]. - The company aims to become a leading platform in the global pharmaceutical industry, providing comprehensive and integrated drug R&D and production services[61]. - In 2023, the company will focus on building capabilities and scale, enhancing its integrated enabling platform to support innovation for clients[62]. Risks and Challenges - The pharmaceutical R&D services industry is highly regulated, and any failure to adapt to changes in industry policies and regulations could have a negative impact on the company's operations[70]. - The company faces intensified competition in the global pharmaceutical R&D services market, particularly from large pharmaceutical companies and specialized CRO/CDMO institutions, which may possess stronger financial and technical capabilities[71]. - The loss of core technical personnel poses a risk to the company's competitive advantage and ongoing profitability, particularly if compensation and incentive mechanisms are not competitive[74].

无锡药明康德新药开发股份有限公司 简式权益变动报告书 上市公司名称：无锡药明康德新药开发股份有限公司 股票上市地点：上海证券交易所、香港联合交易所有限公司 股票简称：药明康德 股票代码：603259.SH、02359.HK | 信息披露义务人 | | 住所 Unit 826, 8/F, Ocean | | 通讯地址 | | | | --- | --- | --- | --- | --- | --- | --- | | Limited | G&C IV Hong Kong | Centre, Harbour City, 5 | | | | | | | | Canton Road, | | 中国上海外高 | | Tst, | | | | Kowloon, Hong Kong | | 桥富特中路 | | | | G&C V Limited | | PO Box 309, Ugland | | 号 | | | | G&C VI Limited | | House, Grand Cayman, | | | 288 | | | G&C VII Limited | | KY1-1104, Cayman | | | | | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-057 无锡药明康德新药开发股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司收到公司实际控制人 Ge Li（李革）、张朝晖和刘晓钟（以下合称"实 际控制人"）控制或与实际控制人签署一致行动协议或签署投票委托书的 22 名 股东（以下合称为"信息披露义务人"）于 2023 年 8 月 30 日出具的《无锡药明 康德新药开发股份有限公司简式权益变动报告书》，现就《前次权益变动报告》 披露以来的本次权益变动相关情况公告如下： 一、本次权益变动基本情况 1、信息披露义务人基本情况 本次权益变动的信息披露义务人为公司实际控制人控制的股东、与实际控制 人签署一致行动协议的股东、与实际控制人签署投票委托书的股东，即 G&C IV Hong Kong Limited（以下简称"G&C IV"）、G&C V Limited（以下简称"G&C V"）、G&C VI Limited（以下简称"G&C VI"）、G&C ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-056 无锡药明康德新药开发股份有限公司 股东减持股份进展暨权益变动比例超过 1%的 提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，无锡药明康德新药开发股份有限公司（以下简称"公 司"）实际控制人控制的股东及与实际控制人签署一致行动协议的股东（以下简 称"减持股东"）合计持有公司 A 股股份 647,696,535 股，占公司截至 2023 年 4 月 17 日总股本的 21.83%。该等股份均为公司首次公开发行 A 股股票并上市前所 取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限售条 件流通股。 本次减持计划的主要内容 | 股东名称 | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | | | --- | --- | --- | --- | --- | --- | --- | | 公司实际控制人控制 | | | | IPO 前 得 | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-055 无锡药明康德新药开发股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2023 年 8 月 1 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2023 年半年度报告》。为了便于广大投资者更全面深入 地了解本公司 2023 年半年度业绩和经营情况，本公司拟于 2023 年 8 月 23 日（星 期三）上午 10:30-11:30 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2023 年半年 度业绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍 关注的问题进行回答。 二、 业绩说明会召开的时间、地点 会议召开时间：2023 年 8 月 23 日（星期三）上午 10: ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-054 无锡药明康德新药开发股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 注：上述持股比例按照公司截至 2023 年 8 月 7 日的总股本 2,968,448,145 股 1 为基础计算。 重要内容提示： 股东持股的基本情况 截至本公告披露日，无锡药明康德新药开发股份有限公司（以下简称"公司"） 股东 Summer Bloom Investments (I) Pte. Ltd.持有公司 A 股股份 159,160,073 股， 占公司截至 2023 年 8 月 7 日总股本的 5.36%，该等股份为其于公司 IPO 前取得 的股份和上市后通过公司权益派发资本公积转增股本取得的股份。 减持计划的主要内容 公司于 2023 年 8 月 8 日收到股东 Summer Bloom Investments (I) Pte. Ltd.发出 的《减持计划告知函》。因基金投资正常退出，Summer Bl ...

Financial Performance - The company reported a total revenue of RMB 5.2 billion for the first half of 2023, representing a year-on-year increase of 15%[2]. - The gross profit margin for the first half of 2023 was 35%, compared to 32% in the same period last year[2]. - The company reported a net profit of RMB 1.1 billion for the first half of 2023, reflecting a net profit margin of 21%[2]. - The management has set a revenue target of RMB 12 billion for the full year 2023, which would represent a growth of 20% compared to 2022[2]. - Net profit attributable to shareholders of the listed company increased by 14.61% year-on-year, reaching RMB 5,313,119,704.09[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 23.67% year-on-year, amounting to RMB 4,761,082,555.91[18]. - Basic earnings per share for the first half of 2023 were RMB 1.81, up 13.84% from RMB 1.59 in the same period last year[17]. - Diluted earnings per share increased by 20.95% to RMB 1.79, compared to RMB 1.48 in the previous year[17]. - The company's total assets reached RMB 69,319,133,730.68, a 7.16% increase from the end of the previous year[16]. - The net cash flow from operating activities was RMB 5,598,180,734.15, reflecting a significant increase of 40.10% compared to the previous year[18]. Client and Market Growth - The number of active clients increased to 1,200, up from 1,050 in the previous year, indicating a growth of approximately 14.3%[2]. - Revenue from the top 20 global pharmaceutical companies accounted for approximately 38% of total revenue, with a year-on-year growth of 47% when excluding specific commercial production projects[28]. - The company served over 6,000 active clients in the past 12 months, with new client additions exceeding 600 during the first half of 2023[29]. - The company continues to drive revenue growth through its unique CRDMO and CTDMO business models[18]. Research and Development - The company plans to expand its R&D capabilities with an investment of RMB 1 billion in new technologies and facilities over the next two years[2]. - The company is focusing on the development of innovative drugs, with 15 new drug candidates currently in the pipeline[2]. - The company aims to enhance its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, peptide drugs, and antibody-drug conjugates, to capture new business opportunities[26]. - The company is positioned to benefit from the increasing outsourcing rates in the pharmaceutical industry, particularly from small and medium-sized biotech firms seeking integrated development services[25]. Environmental Initiatives - The company is committed to sustainability and has implemented new environmental initiatives aimed at reducing carbon emissions by 30% by 2025[2]. - The company reported a total of 33,488.665 tons of hazardous waste collected and disposed of by qualified third parties[83]. - The company has engaged third-party qualified entities for the disposal of hazardous waste, ensuring proper environmental management practices[81]. - The company has implemented measures to reduce emissions of non-methane total hydrocarbons, with a reported emission of 3.142 tons annually[81]. - The company has established a waste management program to oversee the handling of general industrial solid waste and hazardous solid waste, ensuring compliance with national regulations[96]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, which may impact future performance[2]. - The company faced risks related to a potential decline in demand for pharmaceutical R&D services, which could adversely affect business performance[57]. - The company is exposed to regulatory risks in the pharmaceutical R&D services industry, which could impact operations if not managed properly[58]. - The company has established a comprehensive internal control system to ensure compliance with national laws and regulations, but risks remain due to the number of subsidiaries and potential regulatory oversight failures[60]. Corporate Governance - The company elected Ge Li as the chairman and CEO, and Edward Hu as the vice chairman and global chief investment officer during the board meeting on June 6, 2023[74]. - The third supervisory board was elected, with Harry Liang He as the chairman, confirmed during the meeting on June 6, 2023[75]. - The company held its annual general meeting on May 31, 2023, where the third board of directors and supervisors were elected[73]. - The company has not made any progress or changes regarding its stock incentive plan since the last announcement[77]. Shareholder Commitments - The actual controller committed to reducing shareholding within two years after the lock-up period, ensuring the selling price will not be lower than the issuance price, adjusted for rights issues[172]. - The company has established rules for share reduction, including a maximum of 1% of total shares in any 90-day period for centralized bidding transactions[173]. - The commitment also states that any share reduction must be disclosed 15 trading days in advance for centralized bidding transactions[172]. - The actual controller has promised to avoid the misuse of rights to occupy the company's funds and assets, ensuring compliance with relevant laws and regulations[184]. Employee Engagement - The company employs a total of 41,296 staff, with 12,520 holding master's degrees or higher, and 1,374 holding doctoral degrees[22]. - The company continues to focus on stock incentive plans to align employee interests with shareholder value[200]. - The company’s stock incentive plans include multiple phases of restricted share releases, indicating ongoing employee engagement strategies[200].